読み込み中
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
前日終値
$0.993
+$0.0096 · +0.98%
日中の時刻はETです。市場データは遅延する場合があります。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日中レンジ
現在 $0.993
52週レンジ
現在 $0.993
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
33
割高
センチメント
67
強気
リスク
61
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日中レンジ
現在 $0.993
52週レンジ
現在 $0.993
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 85万 USD | — | — | — |
| 売上原価 | 147.2万 USD | — | — | — | — |
| 粗利益 | −147.2万 USD | 85万 USD | — | — | — |
| 研究開発 | 5596.9万 USD | 4234.2万 USD | 3812万 USD | 2999.7万 USD | 2033.7万 USD |
| 販売・一般管理 | 1687万 USD | 1513.3万 USD | 1224.3万 USD | 1165.8万 USD | 1092.7万 USD |
| 営業費用 | 7136.7万 USD | 5747.5万 USD | 5036.3万 USD | 4165.5万 USD | 8188.2万 USD |
| 受取利息 | 635万 USD | 730万 USD | 790万 USD | 236万 USD | 2.9万 USD |
| 支払利息 | — | — | — | 236万 USD | 37万 USD |
| 減価償却費と償却費 | 147.2万 USD | 175.3万 USD | 189万 USD | 190.4万 USD | 162.4万 USD |
| 営業利益 | −7283.9万 USD | −5662.5万 USD | −5036.3万 USD | −4165.5万 USD | −8188.2万 USD |
| 純利益 | −6648.9万 USD | −4937.5万 USD | −4249.4万 USD | −3922.5万 USD | −8218.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.67
上昇余地（370.29%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1001.59万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI479.21万0.05%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF435.36万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 ETFIWM347.57万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Russell 2000 ETFVTWO180.34万0.01%180億 USD0.06%$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM160.54万0.02%64.1億 USD0.28%$45.46+0.46%
Vanguard Health Care ETFVHT69.57万0.00%220億 USD0.09%$319.01+1.64%
iShares Micro-Cap ETFIWC40.39万0.03%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
